Skadden is advising Merrimack Pharmaceuticals, Inc. on the sale of cancer treatment drugs ONIVYDE and generic DOXIL to Ipsen S.A. in an asset sale valued at up to $1.025 billion.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
Skadden is advising Merrimack Pharmaceuticals, Inc. on the sale of cancer treatment drugs ONIVYDE and generic DOXIL to Ipsen S.A. in an asset sale valued at up to $1.025 billion.